AMLN Amylin Pharmaceuticals, Inc. (MM)

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that it has filed a preliminary prospectus supplement to a shelf registration statement with the Securities and Exchange Commission relating to a proposed public offering of 8,500,000 shares of its common stock. The underwriters will be granted the right to purchase up to an additional 1,275,000 shares of common stock to cover over-allotments, if any. All of the shares are being sold by Amylin Pharmaceuticals. Morgan Stanley & Co. Incorporated is acting as the sole bookrunning and joint lead manager for the offering. Goldman, Sachs & Co. is acting as a non-bookrunning joint-lead manager of the offering. Co-managers for the offering are Bear, Stearns & Co. Inc. and Lehman Brothers Inc. These securities may not be sold nor may offers to buy be accepted prior to the time that the prospectus supplement is final. The common stock is being offered in connection with a distribution by the issuer and represents new financing. Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Copies of the preliminary prospectus supplement may be obtained from the Prospectus Department of Morgan Stanley & Co. Incorporated (1585 Broadway, New York, New York 10036, phone 212-761-6775, fax 212-761-0211). DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright